Thought provoking article regarding a non-antibody mediated mechanism in chronic ITP.
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy
Throwback by JCO! Docetaxel vs Pemetrexed in 2L NSCLC showed similar OS/PFS outcomes, but Pemetrexed was tolerated better particularly in terms of myelosuppression. Pemetrexed was active in squamous cancers as well.
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
Pembro + ICE seems to be a compelling option in the 2L setting for transplant eligible cHL patients, however this is not yet in guidelines.
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
Retrospective review showing equivocal outcomes in cT2-T4N0 patients treated with radical cystectomy vs TURBT + chemoradiation. There were similar rates of neoadjuvant chemotherapy being given in both groups. Based on prospective data, the SOC remains cisplatin-based neoadjuvant chemo followed by radical cystectomy; however, trimodality therapy may not have worse outcomes, and it would be great to see a prospective head-to-head study.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
5-year survival data from the Zuma trials shows that there is curative potential in r/r DLBCL with cure rates near 50%.
Not a common disease and not a randomized study, but very good responses seen in oral-Vidaza + CHOP for PTCL.
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538
Twice-Daily radiation therapy is a long-standing SOC for LS-SCLC based upon improved OS in Intergroup0096, published nearly 25 years ago in 1999. This study compared 45 Gy at 1.5 Gy/fx BID vs. 45 Gy at 1.8 Gy/day. This regimen, however, has been slow to be adopted due to the inconvenience of BID therapy, as well as the modest radiation dose in control arm.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
New criteria for response to therapy in high grade MDS, focuses on pt centered outcomes.
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
Neoadjuvant immunotherapy is gaining momentum in breast (triple negative) and lung cancer, now showing promise in MSI high tumors.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
Although immunotherapy did not beat chemotherapy but was non inferior and with more favorable safety.